NCT07035886 A Study to Monitor the Fruzaqla Treatment of Adults With Metastatic Colorectal Cancer (mCRC) in South Korea
| NCT ID | NCT07035886 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Takeda |
| Condition | Colorectal Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2025-09-29 |
| Primary Completion | 2029-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2025-09-29 with a primary completion date of 2029-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to estimate the proportion of all adverse events (AEs) including serious adverse events (SAEs) occurring with the use of fruquintinib among adult participants who have been administered fruquintinib as per the approved indications.
Eligibility Criteria
Inclusion Criteria: * Age greater than or equal to (\>=)18 years. * Participants who are initiate treatment or will be treated with Fruzaqla according to the approved label of South Korea. * Participant voluntarily consent to participate in the study. Exclusion criteria: * Participants for whom Fruzaqla is contraindicated or those with risks that should avoid starting Fruzaqla, as per the product label. * Participants actively participating in other interventional clinical trial(s) on mCRC treatments. * Pregnant or breastfeeding women.
Contact & Investigator
Study Director
STUDY DIRECTOR
Takeda
Frequently Asked Questions
Who can join the NCT07035886 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07035886 currently recruiting?
Yes, NCT07035886 is actively recruiting participants. Contact the research team at medinfoUS@takeda.com for enrollment information.
Where is the NCT07035886 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT07035886 clinical trial?
NCT07035886 is sponsored by Takeda. The principal investigator is Study Director at Takeda. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.